Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - cabozantinib (s)-malate 25.34mg eqv cabozantinib - tablet, film coated - cabozantinib (s)-malate 25.34mg eqv cabozantinib 20mg

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - cabozantinib (s)-malate 50.69mg eqv cabozantinib - tablet, film coated - cabozantinib (s)-malate 50.69mg eqv cabozantinib 40mg

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - cabozantinib (s)-malate 76.03mg eqv cabozantinib - tablet, film coated - cabozantinib (s)-malate 76.03mg eqv cabozantinib 60mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 25.34mg equivalent to cabozantinib 20 mg - film coated tablet - 20 mg - active: cabozantinib s-malate 25.34mg equivalent to cabozantinib 20 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 50.69mg equivalent to cabozantinib 40 mg - film coated tablet - 40 mg - active: cabozantinib s-malate 50.69mg equivalent to cabozantinib 40 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 76.03mg equivalent to cabozantinib 60 mg - film coated tablet - 60 mg - active: cabozantinib s-malate 76.03mg equivalent to cabozantinib 60 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

ipsen pharma - cabozantinib (s- malate) - cabozantinib (s- malate)....20,00 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

ipsen pharma - cabozantinib (s- malate) - cabozantinib (s- malate)....40,00 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

ipsen pharma - cabozantinib (s- malate) - cabozantinib (s- malate)....60,00 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ipsen ltd - cabozantinib s-malate - capsule - 20mg